Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 2Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1307Carcinoma, Renal Cell 660Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 333Neoplasms 301Carcinoma, Transitional Cell 263Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 227Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 97Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Interventions

tempol 1TEMPOL-H 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostate Cancer Recurrent × Genitourinary × Clear all
NCT04114825 2021-09-28

BRaVac

RhoVac APS

Phase 2 Active not recruiting
180 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04734184 2021-02-02

Python

Curium PET France

Phase 3 Unknown
217 enrolled
Genitourinary

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡